Evidence map›Paper›PMID 42763583›Full record

ArticlePsychopharmacology bulletin2026

Olanzapine-Induced Rapid Weight Gain and Metabolic Disorders: A Case Series.

Michal Smogur, Séverine Crettol, Céline Dubath, Frederik Vandenberghe, Georgios Schoretsanitis, Philippe Conus, Chin Bin Eap, Nicolas Ansermot

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michal SmogurSmogur, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
Séverine CrettolCrettol, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. ORCID ID: 0000-0003-3790-7194.
Céline DubathDubath, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. ORCID ID: 0000-0002-6585-8492.
Frederik VandenbergheVandenberghe, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. ORCID ID: 0000-0002-8964-2047.
Georgios SchoretsanitisSchoretsanitis, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland; Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA; Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York, USA. ORCID ID: 0000-0002-3851-4117.
Philippe ConusConus, Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. ORCID ID: 0000-0002-5832-1910.
Chin Bin EapEap, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland; Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland; University of Lausanne, Lausanne, Switzerland. ORCID ID: 0000-0002-5439-0230.
Nicolas AnsermotAnsermot, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. ORCID ID: 0000-0001-8350-9416.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olanzapine is an atypical antipsychotic drug associated with a high risk of weight gain and metabolic disorders. This condition represents both a major health risk for patients and a therapeutic challenge in psychiatric care. We present a series of four cases exhibiting a rapid and severe weight gain under olanzapine treatment, as well as new-onset metabolic syndrome in three of them. The evolution of these disorders after treatment modification is presented for three cases, and strategies for mitigating the risk of metabolic complications in patients receiving antipsychotic drugs are discussed.

Indexed as

Antipsychotic AgentsBenzodiazepinesMetabolic DiseasesMetabolic SyndromeOlanzapineWeight GainAdultFemaleHumansMaleMiddle AgedAntipsychotic AgentsBenzodiazepinesOlanzapinedyslipidaemiahyperglycaemiametabolic syndromeolanzapineweight gain

Identifiers

PMID42763583
PMCPMC13589239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.